Clinical Report
Efficacy of conbercept for macular edema secondary to retinal vein occlusion
Zhang Xuan, Chen Jun, Wang Chongyu
Published 2021-11-05
Cite as Chin J Ocul Traum Occupat Eye Dis, 2021, 43(11): 861-866. DOI: 10.3760/cma.j.cn116022-20210529-00159
Abstract
ObjectiveTo evaluate the efficacy of conbercept for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO).
MethodsThis was a prospective case control study.Total of 91 eyes of 91 cases with macular edema secondary to BRVO from May 2018 to Oct.2020 in Xuzhou Fuxing Ophthalmic Hospital were randomly divided into the control group with 45 cases and the clinical trial group with 46 cases based on the envelope method.The control group was treated with panretinal laser photocoagulation, and the clinical trial group was treated with intravitreal injection of conbercept.The follow-time was 3 months.The therapeutic efficacy and macular microvascular structure between the two groups were compared.
ResultsAfter treatment, the vascular density of the superficial and deep capillaries and the avescular dimension in the macular area of the trial group were higher than that of the control group(t=1.932, 3.382, 3.006; P=0.028, 0.001, 0.002), and the central macular thickness of the trial group was lower than that of the control group (t=2.061, P=0.022). The visual acuity of the trial group was significantly higher than that of the control group (t=6.053, P<0.001). The total effective rate of the clinical trial group was higher than that of the control group(χ2=5.680, P=0.017).
ConclusionIntravitreal injection of conbercept can effectively treat macular edema secondary to BRVO.
Key words:
Anti-vascular endothelial growth factor; Edema, macular, secondary; Occlusion, vein, branch, retinal; Structure, microvascular; Visual acuity
Contributor Information
Zhang Xuan
Xuzhou Fuxing Eye Hospital, Jiangsu 221003, China
Chen Jun
Xuzhou Fuxing Eye Hospital, Jiangsu 221003, China
Wang Chongyu
Changzhou Purui Ophthalmic Hospital, Jiangsu 213000, China
